The Lancet ranking reveals India’s heat blind spot as infants and older adults face rising heatwave exposure and inadequate targeted protection.
Cipla’s respiratory muscle drives US growth, but can its commercial network deliver success with a Keytruda biosimilar in oncology?
Ayushman Bharat's expanding health-data infrastructure could help Indian pharmaceutical researchers evaluate treatment outcomes, strengthen drug safety monitoring and improve real-world evidence.
Cipla’s Rs 423 crore R&D investment signals a long-term growth bet despite a 35% profit decline and weaker US sales.
TROP2 ADC sac-TMT extends survival in advanced endometrial cancer, offering a potential new treatment option after chemotherapy and immunotherapy failure in a late-stage clinical trial.
Eris Lifesciences targets semaglutide market expansion to Rs 80-90 crore monthly by next year, driven by rising demand for diabetes therapies.
GSK and Hansoh's Ris-Rez shows promise in osteosarcoma treatment, reducing progression risk in a Phase III trial and highlighting unmet needs after relapse.
Haryana ends OPD queue hardship with UPI payments and home registration, making public hospital visits faster, simpler and more convenient.
Biocon’s Yesintek gains market entry into nine high-growth markets, expanding its global biosimilar reach through a settlement with Janssen Sciences Ireland.
AIG Hospitals and Boston Scientific are expanding specialist training to support access to advanced gastrointestinal procedures beyond major Indian cities.